glp-1 coverage medicare Bridge Program: What Medicare Beneficiaries Need to Know | Plan Medicare New Medicare GLP-1 Bridge Program

10.1007/s40618-023-02084-6 J Endocrinol Invest

Eur J Pharmacol (2015) 765:4827

Within the brain, agonism of GLP-1 could enhance cognitive function and diminish neuroinflammation and potentially provide a protective effect against diseases that are NDs, including Alzheimers disease and Parkinsons disease

On the other hand, with drugs such as Wegovy, some of the underlying metabolic imbalances may persist

Medications that employ gradual dose escalation over several weeks allow the gastrointestinal system to adapt progressively to the drug's effects

Patients taking Wegovy and stimulant ADHD medications concurrently should maintain regular contact with their healthcare team and be aware of specific circumstances requiring prompt medical attention